Search Results

OncoPep, Inc. is proud to be a presenter at this year’s Biotech Showcase January 9-11 in San Francisco.

OncoPep, Inc. is proud to be a participant at this year’s BIO International Convention 2022 conference June 13-16 in San Diego CA.

OncoPep, Inc. announced it is expanding its Scientific Advisory Board with the addition of Carl Novina, MD, PhD.

OncoPep, Inc. announced a licensing agreement with MANA Therapeutics for use of its EDIFY™ platform for the development of an autologous multi-tumor antigen adoptive T cell therapy for the treatment of multiple myeloma and solid tumors, as an additional T cell focused immunotherapeutic for its product pipeline.

OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating the safety and tolerability of PVX-410.

OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating its investigational vaccine product PVX-410 for the treatment of patients with metastatic triple negative breast cancer (TNBC) who are human leukocyte antigen A2 positive (HLA-A2+).

Oncopeptides AB (STO: ONCO), a biotech company focused on difficult-to-treat cancers, and Vector Pharma FZCO (“Vector”) today announced a collaboration to commercialize Oncopeptides’ flagship drug Pepaxti (melphalan flufenamide) in the Middle East and North Africa (“MENA”) countries of Saudi Arabia, Qatar, UAE, Bahrain, Kuwait, Oman, Algeria, Tunisia, Morocco, Libya, Lebanon, and Iraq.

Oncopeptides AB announces that Holger Lembrer, who recently was appointed Chief Financial Officer, CFO, takes the office on January 18.